Category Business

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Ligand Pharmaceuticals Incorporated announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been…

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai…

Vividion Therapeutics starts Phase I clinical trial in advanced solid tumors with KEAP1 activator Vividion Therapeutics, Inc. (Vividion), announced today that it has initiated dosing of patients in a Phase I oncology clinical trial of its investigational oral Kelch-like ECH…

AstraZeneca advances UK clean heat and energy efficiencies with £100m commitment Powering AstraZeneca’s transition to net zero, the Company has agreed a 15-year partnership with Future Biogas to establish the UK’s first unsubsidised industrial-scale supply of biomethane gas, and is…

Takeda commits more than $30 million to five new global CSR partnerships to boost health impact in 92 countries Takeda today announces five new partnerships for its Global Corporate Social Responsibility (CSR) Program, which contribute to strengthening health systems in…

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced…

AMGEN AND HORIZON THERAPEUTICS PLC RESOLVE FTC LAWSUIT, CLEARING PATH TO CLOSE ACQUISITION Amgen and Horizon Therapeutics plc today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take…

Bayer to invest EUR 220 million in new R&D facility at its Monheim site Bayer significantly strengthens its commitment to innovation in regenerative agriculture with a EUR 220 million investment in research and development (R&D) at its Monheim site. This is the…

Pfizer’s ELREXFIO™ receives U.S. FDA accelerated approval for relapsed or refractory multiple myeloma Pfizer Inc. (NYSE:PFE) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed…

AI drives a new era of target identification and drug design Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact. A new…

MERCK AND MODERNA INITIATE PHASE 3 STUDY EVALUATING V940 (MRNA-4157) IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR ADJUVANT TREATMENT OF PATIENTS WITH RESECTED HIGH-RISK (STAGE IIB-IV) MELANOMA Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and…